公开(公告)号：US20080107630A1

公开(公告)日：2008-05-08

申请号：US11697394

申请日：2007-04-06

申请人： John G. Hay ,  Jin Cheng ,  Harald Sauthoff

发明人： John G. Hay ,  Jin Cheng ,  Harald Sauthoff

IPC分类号： A61K39/12 ,  A61P35/00 ,  C12N9/50

CPC分类号： C12N15/86 ,  A61K35/761 ,  A61K38/00 ,  C12N7/00 ,  C12N9/6491 ,  C12N2710/10332 ,  C12N2710/10343 ,  A61K2300/00

摘要： The present invention discloses a method of treating cancer in a subject. This involves co-administering a replicating virus and a matrix metalloproteinase to the subject under conditions effective to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses. This involves co-administering a replicating virus and a matrix metalloproteinase to the tumor mass under conditions effective to enhance the delivery to and distribution within the tumor mass of therapeutic viruses. Another aspect relates to a cancer therapeutic. This involves a replicating virus and a matrix metalloproteinase.

摘要翻译： 本发明公开了一种治疗受试者的癌症的方法。 这涉及在有效治疗癌症的条件下向受试者共同施用复制病毒和基质金属蛋白酶。 本发明还涉及增强治疗性病毒肿瘤块内的传递和分布的方法。 这涉及在有效增强在治疗性病毒的肿瘤块内递送和分布的条件下，将复制病毒和基质金属蛋白酶共同施用于肿瘤块。 另一方面涉及癌症治疗剂。 这涉及复制病毒和基质金属蛋白酶。

公开(公告)号：US20060247188A1

公开(公告)日：2006-11-02

申请号：US11096082

申请日：2005-03-29

申请人： Jin Cheng ,  Said Sebti

发明人： Jin Cheng ,  Said Sebti

IPC分类号： A61K31/7076

CPC分类号： C07H17/02 ,  A61K31/7064

摘要： The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.

公开(公告)号：US20090286761A1

公开(公告)日：2009-11-19

申请号：US12191209

申请日：2008-08-13

申请人： Jin Cheng ,  Stephen Dugan ,  Gordon Stewart ,  Gina Zhang ,  Nancy Kirsten ,  Paul Consigny ,  Christopher Feezor ,  Gene Park ,  Wouter Roorda ,  Syed F.A. Hossainy

发明人： Jin Cheng ,  Stephen Dugan ,  Gordon Stewart ,  Gina Zhang ,  Nancy Kirsten ,  Paul Consigny ,  Christopher Feezor ,  Gene Park ,  Wouter Roorda ,  Syed F.A. Hossainy

IPC分类号： A61K31/56 ,  A61P7/00

CPC分类号： A61L31/16 ,  A61F2/91 ,  A61F2250/0067 ,  A61F2250/0068 ,  A61K31/4745 ,  A61K31/56 ,  A61K31/573 ,  A61L31/10 ,  A61L31/148 ,  A61L2300/222 ,  A61L2300/416 ,  A61L2300/45 ,  A61K2300/00

摘要： A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

摘要翻译： 提供了一种药物递送系统，其包括至少100杯依维莫司和氯倍他索，使得依维莫司与氯倍他索的比例至少为10：1（w / w），依维莫司的重量比为至少10倍 氯倍他索 该系统可以是支架。 还提供了治疗血管的再狭窄或易损斑块的方法，所述方法包括向患者局部施用选自雷帕霉素（西罗莫司），Biolimus A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司， 40-（2-羟基）乙基雷帕霉素（依维莫司），40-O-（3-羟基）丙基雷帕霉素，40-O- [2-（2-羟基）乙氧基]乙基雷帕霉素，40- O-四唑基雷帕霉素和40-表 - （N1-四唑基）雷帕霉素，并且对患者局部施用由氯倍他索组成的第二药物，其中局部施用的第一药物的最小量为100杯，其中 第二种药物的第一种药物例如为10：1〜100：1（w / w）。

公开(公告)号：US20060253088A1

公开(公告)日：2006-11-09

申请号：US11112546

申请日：2005-04-22

申请人： Mina Chow ,  Dwight Ambat ,  Jin Cheng ,  Eugene Michal

发明人： Mina Chow ,  Dwight Ambat ,  Jin Cheng ,  Eugene Michal

IPC分类号： A61M25/00

CPC分类号： A61M25/06 ,  A61M25/003 ,  A61M25/0071 ,  A61M2025/0034 ,  A61M2025/0037

摘要： An apparatus for delivering devices. The apparatus comprises a catheter with an elongated shaft having a first lumen and a second lumen extending therethrough. The apparatus further comprises a distal section with a lumen in communication with a port in a distal end of the catheter and with the first lumen and the second lumen. The first lumen is configured for a first device and the second lumen is configured for a second device to be disposed therein. The apparatus further comprises a proximal adapter coupled to the elongated shaft with a first port in communication with the first lumen and a second port in communication with the second lumen.

公开(公告)号：US20060030536A1

公开(公告)日：2006-02-09

申请号：US11102911

申请日：2005-04-08

申请人： Hua Yu ,  Richard Jove ,  Jin Cheng ,  Guilian Niu ,  Said Sebti

发明人： Hua Yu ,  Richard Jove ,  Jin Cheng ,  Guilian Niu ,  Said Sebti

IPC分类号： A61K48/00 ,  A61K39/395

CPC分类号： C12N15/1135 ,  A61K31/282 ,  A61K31/7064 ,  A61K39/395 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  C12N2320/31 ,  A61K2300/00

摘要： Compositions and methods for treating cancer and proliferative angiopathies are provided. A composition can include an inhibitor of the Jak2/Stat3 signaling pathway and an inhibitor of the PI3k/Akt signaling pathway. In certain cases, the two inhibitors are capable of acting synergistically as compared to either inhibitor alone.

摘要翻译： 提供了治疗癌症和增殖性血管病的组合物和方法。 组合物可以包括Jak2 / Stat3信号通路的抑制剂和PI3k / Akt信号通路的抑制剂。 在某些情况下，与单独的抑制剂相比，两种抑制剂能够协同作用。

公开(公告)号：US07733170B2

公开(公告)日：2010-06-08

申请号：US11913131

申请日：2007-05-09

申请人： Jin Cheng

发明人： Jin Cheng

IPC分类号： H03F3/38 ,  H03F3/217

CPC分类号： H03F3/2173 ,  H03F1/32

摘要： The present invention discloses a switching amplifier and its modulations process, which belongs to the field of non-filters-type switching amplifier. The switching amplifier comprises: pulse-width modulation with dual comparator, multiple-loop feedback structure, only one integrating amplifier with dual-ends output needed for each loop, no less than two feedback loops set between the integrating amplifier and H-bridge, in addition, no any low-pass filters needed adding to the feedback path. Multiple feedback loops are adopted in the present invention, which can low the distortion of the switching amplifier to the extent. Furthermore, no any extra low-pass filters are needed adding to the feedback path, which making the products a higher cost effectiveness.

摘要翻译： 本发明公开了一种属于非滤波型开关放大器领域的开关放大器及其调制过程。 开关放大器包括：具有双比较器的脉宽调制，多回路反馈结构，每个环路只需要一个具有双端输出的积分放大器，在积分放大器和H桥之间设置不少于两个反馈回路， 此外，没有任何低通滤波器需要添加到反馈路径。 在本发明中采用多反馈环路，这可以使开关放大器的失真程度降低。 此外，没有任何额外的低通滤波器需要添加到反馈路径，这使得产品具有更高的成本效益。

公开(公告)号：US20090115508A1

公开(公告)日：2009-05-07

申请号：US11913131

申请日：2007-05-09

申请人： Jin Cheng

发明人： Jin Cheng

IPC分类号： H03F3/217 ,  H03F3/38

CPC分类号： H03F3/2173 ,  H03F1/32

摘要： The present invention discloses a switching amplifier and its modulations process, which belongs to the field of non-filters-type switching amplifier. The switching amplifier comprises; pulse-width modulation with dual comparator, multiple-loop feedback structure, only one integrating amplifier with dual-ends output needed for each loop, no less than two feedback loops set between the integrating amplifier and H-bridge, in addition, no any low-pass filters needed adding to the feedback path. Multiple feedback loops are adopted in the present invention, which can low the distortion of the switching amplifier to the extent. Furthermore, no any extra low-pass filters are needed adding to the feedback path, which making the products a higher cost effectiveness.

摘要翻译： 本发明公开了一种属于非滤波型开关放大器领域的开关放大器及其调制过程。 开关放大器包括： 具有双比较器的脉冲宽度调制，多环路反馈结构，每个环路只需要一个具有双端输出的积分放大器，在积分放大器和H桥之间设置不少于两个反馈回路，此外，没有任何低 通过滤波器需要添加到反馈路径。 在本发明中采用多反馈环路，这可以使开关放大器的失真程度降低。 此外，没有任何额外的低通滤波器需要添加到反馈路径，这使得产品具有更高的成本效益。

公开(公告)号：US09149602B2

公开(公告)日：2015-10-06

申请号：US11112546

申请日：2005-04-22

申请人： Mina Chow ,  Dwight A. Ambat ,  Jin Cheng ,  Eugene Michal

发明人： Mina Chow ,  Dwight A. Ambat ,  Jin Cheng ,  Eugene Michal

IPC分类号： A61M25/00 ,  A61M25/06

CPC分类号： A61M25/06 ,  A61M25/003 ,  A61M25/0071 ,  A61M2025/0034 ,  A61M2025/0037

摘要： An apparatus for delivering devices. The apparatus comprises a catheter with an elongated shaft having a first lumen and a second lumen extending therethrough. The apparatus further comprises a distal section with a lumen in communication with a port in a distal end of the catheter and with the first lumen and the second lumen. The first lumen is configured for a first device and the second lumen is configured for a second device to be disposed therein. The apparatus further comprises a proximal adapter coupled to the elongated shaft with a first port in communication with the first lumen and a second port in communication with the second lumen.

摘要翻译： 一种用于传送设备的设备。 该装置包括具有细长轴的导管，该细长轴具有第一内腔和延伸穿过其中的第二腔。 该装置还包括远端部分，其具有与导管的远端中的端口以及与第一管腔和第二管腔连通的内腔。 第一管腔被配置为用于第一装置，并且第二管腔被配置为用于设置在其中的第二装置。 所述装置还包括：与所述细长轴相连的近端适配器，其具有与所述第一管腔连通的第一端口和与所述第二管腔连通的第二端口。

公开(公告)号：US08435550B2

公开(公告)日：2013-05-07

申请号：US12191209

申请日：2008-08-13

申请人： Jin Cheng ,  Stephen Dugan ,  Gordon Stewart ,  Gina Zhang ,  Nancy Kirsten ,  Paul Consigny ,  Christopher Feezor ,  Gene Park ,  Wouter Roorda ,  Syed F. A. Hossainy

发明人： Jin Cheng ,  Stephen Dugan ,  Gordon Stewart ,  Gina Zhang ,  Nancy Kirsten ,  Paul Consigny ,  Christopher Feezor ,  Gene Park ,  Wouter Roorda ,  Syed F. A. Hossainy

IPC分类号： A61F2/02

CPC分类号： A61L31/16 ,  A61F2/91 ,  A61F2250/0067 ,  A61F2250/0068 ,  A61K31/4745 ,  A61K31/56 ,  A61K31/573 ,  A61L31/10 ,  A61L31/148 ,  A61L2300/222 ,  A61L2300/416 ,  A61L2300/45 ,  A61K2300/00

摘要： A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

摘要翻译： 提供了一种药物递送系统，其包括至少100杯依维莫司和氯倍他索，使得依维莫司与氯倍他索的比例至少为10：1（w / w），依维莫司的重量比为至少10倍 氯倍他索 该系统可以是支架。 还提供了治疗血管的再狭窄或易损斑块的方法，所述方法包括向患者局部施用选自雷帕霉素（西罗莫司），Biolimus A9，deforolimus，AP23572，他克莫司，替西罗莫司，吡美莫司， 40-（2-羟基）乙基雷帕霉素（依维莫司），40-O-（3-羟基）丙基雷帕霉素，40-O- [2-（2-羟基）乙氧基]乙基雷帕霉素，40- O-四唑基雷帕霉素和40-表 - （N1-四唑基）雷帕霉素，并且对患者局部施用由氯倍他索组成的第二药物，其中局部施用的第一药物的最小量为100杯，其中 第二种药物的第一种药物例如为10：1〜100：1（w / w）。

公开(公告)号：US20080020014A1

公开(公告)日：2008-01-24

申请号：US11879297

申请日：2007-07-17

申请人： Paul Consigny ,  Jin Cheng ,  Wouter Erik Roorda

发明人： Paul Consigny ,  Jin Cheng ,  Wouter Erik Roorda

IPC分类号： A61K9/00 ,  A61K31/4436 ,  A61K31/56 ,  A61K9/14 ,  A61P15/00 ,  A61P9/00 ,  A61P9/10 ,  A61P35/00 ,  A61P1/00 ,  A61K9/127 ,  A61K31/711

CPC分类号： A61L31/16 ,  A61L2300/432 ,  A61L2300/45

摘要： The present invention is directed to implantable devices (e.g., drug-delivery stents) containing nuclear receptor ligands. The nuclear receptor ligands may be, inter alia, PPAR ligands or retinoids. The invention also provides for a method of treating or preventing vascular disorders (e.g., restenosis) and related disorders using the nuclear receptor ligand-containing devices.

摘要翻译： 本发明涉及含有核受体配体的可植入装置（例如药物递送支架）。 核受体配体尤其可以是PPAR配体或类视色素。 本发明还提供了使用含有核受体配体的装置治疗或预防血管疾病（例如再狭窄）和相关疾病的方法。